The new generation blood test : easy and effective
Early detection saves lives
Colox® is a a new generation blood-based test for early detection of colorectal cancer. It is clinically validated and currently available through clinical laboratories in Switzerland. Colox® has proven to have significant benefits:
- It accurately and reliably detects both adenomatous polyps and early stages of colorectal cancer
- It offers a convenient solution for patients to be tested with no need for bowel or stool preparation
- It can be ordered by the physician as part of a routine medical check-up
Colox® has been validated through a multi-center clinical study in Switzerland detecting 78% of colorectal cancer patients, and 52% of patients with adenomatous polyps.
How does Colox® work?
Colox® is a molecular test that measures the immune system response to colorectal lesions. In the presence of adenomatous polyps or colon cancer, Peripheral Blood Mononuclear Cells (PBMC) will modify their gene expression profile. Colox® is based on the analysis of these cells, isolated from a routine blood sample. The molecular test will measure the modification of the PBMCs expression profile using an algorithm to give a positive or negative result.
Learn more about the test.
Individuals testing positive with Colox® have high probability to present colorectal lesions and are referred for follow-up diagnostic colonoscopy for final diagnosis.
Individuals testing negative with Colox® have no colorectal lesion with high probability and should continue periodic testing at intervals recommended by their physician.
Colox® is intended for women and men with an average risk of colorectal cancer, aged 50 and over and without symptom of colorectal cancer.
If you want to do the test, talk with your physician. The Colox test can be prescribed by your general practitioner. Print this “Information for doctors” and ask your doctor for advice. The blood sample can be taken at your doctor’s office or at a medical laboratory. The results of the test will be sent to you by your doctor.
Colox Timeline from 2007 to now
What you need to know about the Colox® test
> What is Colox® ?
Colox® is an easy and efficient blood test for the detection of colorectal tumours and adenomatous polyps. Colox® is a screening test which identifies the high-risk cases of colorectal cancer and directs patients to a colonoscopy diagnosis when needed.
> How does Colox® work ?
Colox® is a molecular test which combines 29 RNA biomarkers with 2 protein tumor markers to give a positive or negative result. RNA markers, changed during the initial stages of the development of a lesion, allow for its early detection. The 2 proteins ensure its specificity. The variation of these biomarkers can signify the presence of a colorectal tumor which will be confirmed thanks to a colonoscopy.
Read more : Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer
> Who can do a Colox® test?
Colox® is a screening test for the prevention and the early detection of colorectal cancer. The test is intended for women and men with an average risk of colorectal cancer: aged 50 and over, no symptom of colorectal cancer, no history of cancer or hereditary syndromes or chronic inflammatory bowel disease.
> Who can’t do a Colox® test?
Colox® is not recommended for people who have a higher risk of colorectal cancer than average with:
- A personal history of adenomatous polyps or colorectal cancer
- A first-degree family history of colorectal cancer
- A family and/or personal history of a high-risk hereditary syndrome such as: Lynch syndrome (HNPCC), familial adenomatous polyps (FAP), etc
- A family and/or personal history of a high risk hereditary syndrome such as: Lynch syndrome (HNPCC), familial adenomatous polyps (FAP), etc
- A personal history of chronic inflammatory bowel disease (CIBD), Crohn’s disease, haemorrhagic recto colitis (HRC), etc